New formulation of a recombinant anthrax vaccine stabilised with structurally modified plant viruses

Anthrax is a disease caused by Bacillus anthracis . The most promising approach to the development of anthrax vaccine is use of the anthrax protective antigen (PA). At the same time, recombinant PA is a very unstable protein. Previously, the authors have designed a stable modified recombinant anthra...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in microbiology Vol. 13; p. 1003969
Main Authors:	Granovskiy, Dmitriy L., Ryabchevskaya, Ekaterina M., Evtushenko, Ekaterina A., Kondakova, Olga A., Arkhipenko, Marina V., Kravchenko, Tatiana B., Bakhteeva, Irina V., Timofeev, Vitalii S., Nikitin, Nikolai A., Karpova, Olga V.
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 09-09-2022
Subjects:	adjuvant anthrax Microbiology plant virus protective antigen (PA) tobacco mosaic virus vaccine candidate
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Anthrax is a disease caused by Bacillus anthracis . The most promising approach to the development of anthrax vaccine is use of the anthrax protective antigen (PA). At the same time, recombinant PA is a very unstable protein. Previously, the authors have designed a stable modified recombinant anthrax protective antigen with inactivated proteolytic sites and substituted deamidation sites (rPA83m). As a second approach to recombinant PA stabilisation, plant virus spherical particles (SPs) were used as a stabiliser. The combination of these two approaches was shown to be the most effective. Here, the authors report the results of a detailed study of the stability, immunogenicity and protectiveness of rPA83m + SPs compositions. These compositions were shown to be stable, provided high anti-rPA83m antibody titres in guinea pigs and were able to protect them from a fully virulent 81/1 Bacillus anthracis strain. Given these facts, the formulation of rPA83m + SPs compositions is considered to be a prospective anthrax vaccine candidate.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Piyush Baindara, University of Missouri, United States Reviewed by: Richa Dwivedi, University of Pittsburgh, United States; Zeeshan Ahmad, Wayne State University, United States; Jagpreet Singh Nanda, Cedars Sinai Medical Center, United States These authors have contributed equally to this work and share first authorship This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology
ISSN:	1664-302X 1664-302X
DOI:	10.3389/fmicb.2022.1003969